HOLD with hard stop at $146; patient entry at technically validated levels; position sizing of 2-3%

• Forward PE of 20.7x is priced on EPS $7.24 bull case vs TTM $4.57 — a $2.12 gap even after Q1 FY26 record of $1.28 (annualized $5.12)
• Revenue growth decelerated sharply from 15.3% in FY24 to 3.0% in FY25 — margin expansion of 980 bps cannot continue indefinitely into flat top-line
• Trailing PE of 33x would expand to 40x on earnings mean-reversion, causing 20-30% multiple compression in stock price
• Price at $148.98 is essentially AT the 50 SMA ($148.75) with prior session low piercing it at $146.97; MACD histogram at -1.79 and widening; RSI at 42 with downward slope one bad session from breaking below 40
• VWMA at $156 with price $7 below indicates path of least resistance is down; previous 'coiled spring' setup at $165 preceded August drawdown
• Equinor deal represents only 0.11% of revenue annually — does not move near-term earnings; frame agreements are floors not ceilings
• Drawdown risk to 200 SMA is approximately 10% from entry; sizing at 5-6% turns manageable loss into portfolio-level event vs 2-3% recommended
• Fed on-hold at 89% probability keeps rates elevated, compressing present value of future earnings
• Discipline is about surviving when wrong; approach is to wait for market confirmation before committing capital

→ vs aggressive: Forward PE of 20.7x anchored on EPS $7.24 bull case is not base case — Q1 FY26 annualized is only $5.12, leaving $2.12 gap that requires 'heroic execution'

→ vs aggressive: Revenue decelerated from 15.3% to 3.0% — 'accelerating industrial capex' claim unsupported; company guidance signals cycle moderation, not acceleration

→ vs aggressive: 7% recession probability understates near-term risk — recessions move fast and market prices 20-30% damage before probability reaches 50%

→ vs aggressive: Waiting for pullback is not market timing — it's disciplined entry management; price already pulled back 10% from $165.79 to $148.98, proving thesis-dependent entries are costly

→ vs aggressive: Equinor deal is 0.11% of revenue annually — qualitative narrative doesn't equal quantitative impact; multiple expansion from 'signaling value' is fragile

→ vs aggressive: Technical 'coiled spring' call is same pattern that preceded August drawdown from $165; MACD negative at -1.79 and widening, RSI 42 with downward slope — not bullish setup

→ vs aggressive: Sizing up to 5-6% because setup is 'asymmetric' is how concentrated losses happen; ATR $4.02 means stop at $146 is already $3 risk, with 200 SMA another $7 down for 10% total drawdown risk

HOLD existing position; wait for 153.70 bullish trigger with 2-3% position sizing over 2-3 tranches if confirmed; exit existing positions if price closes below 146 on volume; do not chase at 200 SMA as a new entry point

• Q1 FY26 EPS record at $1.28; operating margins expanded from 17.1% to 26.9% over four years
• 33x trailing PE pricing in 7.24 forward EPS versus Q1 annualized 5.12 run rate (2.12 dollar gap)
• Revenue growth decelerated from 15.3% to 3.0%
• ATR is 4.02; current price 148.98; stop at 146 (less than one ATR of room)
• Bullish trigger at 153.70 requires daily close above 10 EMA with RSI above 50 and MACD bullish crossover
• Price at 50 SMA with MACD histogram widening negative and VWMA confirming selling pressure
• Long-term structure intact: price above 200 SMA; March-to-August trend from 122 to 165 still dominant move; 38% retracement not equivalent to trend reversal
• Position sizing: 2-3% over 2-3 tranches if trigger fires; existing holders use 146 stop
• EMR has elevated beta of 1.24 for an industrial; evaluate against total portfolio industrials exposure cap
• Macro backdrop: soft landing at 93% probability, Fed on hold at 89%—supports holding quality but not chasing extended names
• If price closes below 146 on volume before trigger fires, stay out entirely and reassess thesis rather than using 200 SMA at 141.50 as entry

→ vs aggressive: Calling the 153.70 trigger 'WILL fire' shows overconfidence rather than probabilistic thinking; ATR-based risk means less than one ATR of room from current levels, making aggressive sizing inappropriate

→ vs conservative: Framing bearish technicals as dominant signal misses that long-term structure remains intact (above 200 SMA, March-to-August uptrend still dominant); 38% retracement is not a trend reversal

→ vs conservative: The 'patient entry' framing is partially self-deception—waiting for 200 SMA test is itself a directional bet that price will get there, not a neutral strategy

→ vs conservative: Recession argument doesn't support the case when prediction markets price only 7% odds; positioning for a 7% tail event with base case allocation is inappropriate

→ vs aggressive: Quality fundamentals do not override near-term price action; 'waiting is risky' is true but insufficient to outweigh actual negative momentum on a 10% drawdown from highs